Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065450 | 0.84 | HTT (0.39) | HTTKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3065398 | 0.84 | HTT (0.39) | HTTKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3063507 | 0.84 | KDM4E (0.34) | HTTKDM4E | |
| SCHEMBL3069860 | 0.84 | HTT (0.44) | HTTKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3067923 | 0.83 | KDM4E (0.39) | HTTKDM4EALDH1A1MAPT | |
| SCHEMBL3058039 | 0.82 | KDM4E (0.34) | HTTKDM4E | |
| SCHEMBL3062348 | 0.82 | ERN1 (0.38) | HTTKDM4EALDH1A1MAPTHPGD | |
| SCHEMBL3052347 | 0.81 | KDM4E (0.37) | HTTKDM4EALDH1A1MAPT | |
| SCHEMBL3070258 | 0.80 | KDM4E (0.39) | HTTKDM4EMAPT | |
| SCHEMBL3066942 | 0.80 | KDM4E (0.37) | HTTKDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261719-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2010-10-14 | — | — | US | disclosed |
| EP-2193132-A2 | 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AstraZeneca AB (SE) | 2010-06-09 | — | — | EP | disclosed |
| WO-2009004382-A2 | 3-SPIROPYRIMIDINETRIONE-QUINOLINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | ASTRAZENECA AB (SE) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261719-A1 | CHEMICAL COMPOUNDS | NCOA3, NR4A3, NR0B2 | HTT 2271/4885KDM4E 4486/4885ALDH1A1 2604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.